Dopamine agonist-based strategies in the treatment of Parkinson's disease

Angelo Antonini, Paolo Barone

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

More therapeutic options have become available for Parkinson's disease (PD) in recent years, leading to significant improvements in motor control both at early and advanced disease stages. More importantly, the need to expand disease management beyond motor symptom control has been recently highlighted and contribution of non-motor features to quality of life is now relevant. Dopamine agonists represent a valid therapeutic option in PD and their effect on non-motor domains like mood or cognition is now acknowledged as a key factor in fully addressing patients' needs. Pramipexole is a well established dopamine agonist that is currently being investigated for its potential disease-modifying effect and action on mood in PD. In this review we will examine factors contributing to treatment decision-making and discuss how a proper balance between motor and non-motor features should be aimed for in approaching PD therapy.

Original languageEnglish
JournalNeurological Sciences
Volume29
Issue numberSUPPL. 5
DOIs
Publication statusPublished - 2008

Fingerprint

Dopamine Agonists
Parkinson Disease
Therapeutics
Disease Management
Cognition
Decision Making
Quality of Life

Keywords

  • Dopamine agonists
  • Dyskinesias
  • Levodopa
  • Motor fluctuations
  • Motor symptoms
  • Non-motor symptoms
  • Parkinson's disease
  • Pramipexole

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Dopamine agonist-based strategies in the treatment of Parkinson's disease. / Antonini, Angelo; Barone, Paolo.

In: Neurological Sciences, Vol. 29, No. SUPPL. 5, 2008.

Research output: Contribution to journalArticle

Antonini, Angelo ; Barone, Paolo. / Dopamine agonist-based strategies in the treatment of Parkinson's disease. In: Neurological Sciences. 2008 ; Vol. 29, No. SUPPL. 5.
@article{157b91eb9e4b4c9991b3a7c893532feb,
title = "Dopamine agonist-based strategies in the treatment of Parkinson's disease",
abstract = "More therapeutic options have become available for Parkinson's disease (PD) in recent years, leading to significant improvements in motor control both at early and advanced disease stages. More importantly, the need to expand disease management beyond motor symptom control has been recently highlighted and contribution of non-motor features to quality of life is now relevant. Dopamine agonists represent a valid therapeutic option in PD and their effect on non-motor domains like mood or cognition is now acknowledged as a key factor in fully addressing patients' needs. Pramipexole is a well established dopamine agonist that is currently being investigated for its potential disease-modifying effect and action on mood in PD. In this review we will examine factors contributing to treatment decision-making and discuss how a proper balance between motor and non-motor features should be aimed for in approaching PD therapy.",
keywords = "Dopamine agonists, Dyskinesias, Levodopa, Motor fluctuations, Motor symptoms, Non-motor symptoms, Parkinson's disease, Pramipexole",
author = "Angelo Antonini and Paolo Barone",
year = "2008",
doi = "10.1007/s10072-008-1049-4",
language = "English",
volume = "29",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Dopamine agonist-based strategies in the treatment of Parkinson's disease

AU - Antonini, Angelo

AU - Barone, Paolo

PY - 2008

Y1 - 2008

N2 - More therapeutic options have become available for Parkinson's disease (PD) in recent years, leading to significant improvements in motor control both at early and advanced disease stages. More importantly, the need to expand disease management beyond motor symptom control has been recently highlighted and contribution of non-motor features to quality of life is now relevant. Dopamine agonists represent a valid therapeutic option in PD and their effect on non-motor domains like mood or cognition is now acknowledged as a key factor in fully addressing patients' needs. Pramipexole is a well established dopamine agonist that is currently being investigated for its potential disease-modifying effect and action on mood in PD. In this review we will examine factors contributing to treatment decision-making and discuss how a proper balance between motor and non-motor features should be aimed for in approaching PD therapy.

AB - More therapeutic options have become available for Parkinson's disease (PD) in recent years, leading to significant improvements in motor control both at early and advanced disease stages. More importantly, the need to expand disease management beyond motor symptom control has been recently highlighted and contribution of non-motor features to quality of life is now relevant. Dopamine agonists represent a valid therapeutic option in PD and their effect on non-motor domains like mood or cognition is now acknowledged as a key factor in fully addressing patients' needs. Pramipexole is a well established dopamine agonist that is currently being investigated for its potential disease-modifying effect and action on mood in PD. In this review we will examine factors contributing to treatment decision-making and discuss how a proper balance between motor and non-motor features should be aimed for in approaching PD therapy.

KW - Dopamine agonists

KW - Dyskinesias

KW - Levodopa

KW - Motor fluctuations

KW - Motor symptoms

KW - Non-motor symptoms

KW - Parkinson's disease

KW - Pramipexole

UR - http://www.scopus.com/inward/record.url?scp=65449145955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449145955&partnerID=8YFLogxK

U2 - 10.1007/s10072-008-1049-4

DO - 10.1007/s10072-008-1049-4

M3 - Article

C2 - 19381765

AN - SCOPUS:65449145955

VL - 29

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 5

ER -